Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $21

Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $21

Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price target from $37 to $21.

August 23, 2022

1 minute read

Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price target from $37 to $21.

Where Zillow Gr Stands With Analysts

November 4, 1:07 PM

Analysts have provided the following ratings for Zillow Gr (NASDAQ:Z) within the last quarter:

October 26, 10:29 AM

Citigroup analyst Arren Cyganovich maintains Synchrony Finl (NYSE:SYF) with a Buy and raises the price target from $42 to $44.

August 31, 4:59 AM

Piper Sandler analyst Matt O'Brien initiates coverage on Miromatrix Medical (NASDAQ:MIRO) with a Overweight rating and announces Price Target of $8.